The G1 Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, Data-Driven rating system and does not include human intervention.
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
What was G1 Therapeutics’s price range in the past 12 months?
G1 Therapeutics lowest stock price was $10.81 and its highest was $37.07 in the past 12 months.
What is G1 Therapeutics’s market cap?
G1 Therapeutics’s market cap is $924.37M.
What is G1 Therapeutics’s price target?
The average price target for G1 Therapeutics is $59.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $68.00 ,the lowest forecast is $51.00. The average price target represents 170.82% Increase from the current price of $21.97.
What do analysts say about G1 Therapeutics?
G1 Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
When is G1 Therapeutics’s upcoming earnings report date?
G1 Therapeutics’s upcoming earnings report date is Aug 11, 2021 which is next month.
How were G1 Therapeutics’s earnings last quarter?
G1 Therapeutics released its earnings results on May 05, 2021. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$1.072 by $0.422.
Is G1 Therapeutics overvalued?
According to Wall Street analysts G1 Therapeutics’s price is currently Undervalued.
Does G1 Therapeutics pay dividends?
G1 Therapeutics does not currently pay dividends.
What is G1 Therapeutics’s EPS estimate?
G1 Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does G1 Therapeutics have?
G1 Therapeutics has 42,070,000 shares outstanding.
What happened to G1 Therapeutics’s price movement after its last earnings report?
G1 Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$1.072. Following the earnings report the stock price went down -3.501%.
Which hedge fund is a major shareholder of G1 Therapeutics?
Among the largest hedge funds holding G1 Therapeutics’s share is Caxton Associates LP. It holds G1 Therapeutics’s shares valued at N/A.